Cotelli Maria, Baglio Francesca, Manenti Rosa, Blasi Valeria, Galimberti Daniela, Gobbi Elena, Pagnoni Ilaria, Rossetto Federica, Rotondo Emanuela, Esposito Valentina, De Icco Roberto, Giudice Carla, Tassorelli Cristina, Catricalà Eleonora, Perini Giulia, Alaimo Cristina, Campana Elena, Benussi Luisa, Ghidoni Roberta, Binetti Giuliano, Carandini Tiziana, Cappa Stefano Francesco
Neuropsychology Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.
IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy.
Brain Sci. 2023 Jul 12;13(7):1060. doi: 10.3390/brainsci13071060.
Primary Progressive Aphasia (PPA) is a syndrome due to different neurodegenerative disorders selectively disrupting language functions. PPA specialist care is underdeveloped. There are very few specialists (neurologists, psychiatrists, neuropsychologists, and speech therapists) and few hospital- or community-based services dedicated to the diagnosis and continuing care of people with PPA. Currently, healthcare systems struggle to provide adequate coverage of care that is too often fragmented, uncoordinated, and unresponsive to the needs of people with PPA and their families. Recently, attention has been gained by non-invasive brain stimulation techniques that allow a personalized treatment approach, such as transcranial Direct Current Stimulation (tDCS). The MAINSTREAM trial looks forward to introducing and evaluating therapeutic innovations such as tDCS coupled with language therapy in rehabilitation settings. A Multimodal Approach for Clinical Diagnosis and Treatment of Primary Progressive Aphasia, MAINSTREAM (ID: 3430931) was registered in the clinicaltrials.gov database (identifier: NCT05730023) on 15 February 2023.
原发性进行性失语（PPA）是一种由不同神经退行性疾病引起的综合征，这些疾病会选择性地破坏语言功能。PPA专科护理尚不完善。专科医生（神经科医生、精神科医生、神经心理学家和言语治疗师）非常少，而且很少有专门针对PPA患者的诊断和持续护理的医院或社区服务。目前，医疗系统难以提供足够的护理覆盖，这些护理往往零散、不协调，无法满足PPA患者及其家人的需求。最近，非侵入性脑刺激技术受到了关注，这些技术允许采用个性化治疗方法，如经颅直流电刺激（tDCS）。MAINSTREAM试验期待在康复环境中引入并评估tDCS与语言治疗相结合等治疗创新方法。原发性进行性失语的多模式临床诊断与治疗方法MAINSTREAM（编号：3430931）于2023年2月15日在clinicaltrials.gov数据库中注册（标识符：NCT05730023）。
